A motion filed by Asahi Kasei Pharma Corporation (Headquarters: Chiyoda-ku, Tokyo, President: Yoshikazu Aoki, the “Company”) in the United States District Court for the Southern District of New York for preliminary injunction requiring Endo Ventures Limited (Headquarters: Dublin, Ireland) et al. to continue to supply the Company with “XIAFLEX^® injection” (generic name: collagenase (clostridium histolyticum), the “Pharmaceutical”) for the treatment of Dupuytren’s Contracture was denied on January 7, 2020 (EST).

The Company is currently studying options to enable the steady supply of the Pharmaceutical, including appeal against the denial of said motion.

The background of this matter is described in the press release entitled “Filing of Complaint for Injunctive Relief requesting for continuous supply of XIAFLEX^® injection” dated October 1, 2019.